TW393479B - Stable 8-alkoxy quinolone carboxylic acid hydrate and the preparation thereof - Google Patents
Stable 8-alkoxy quinolone carboxylic acid hydrate and the preparation thereof Download PDFInfo
- Publication number
- TW393479B TW393479B TW084113176A TW84113176A TW393479B TW 393479 B TW393479 B TW 393479B TW 084113176 A TW084113176 A TW 084113176A TW 84113176 A TW84113176 A TW 84113176A TW 393479 B TW393479 B TW 393479B
- Authority
- TW
- Taiwan
- Prior art keywords
- methyl
- hydrate
- scope
- dihydro
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
Description
修 五、發明説明(2 ) 4 基-卜哌阱基)-4 -氣-3-丨f啉羧酸1/2水合物随濕度之上 | 昇而重量增加,若作成錠劑時有崩散性及溶出性不佳等 裂劑化上問題。 '心 發明之掲示 . 卜 . 本發明者們為解決上述1-瓌丙基-6-毎:-1,4-二氳-8- 甲氣基-7-(3 -甲基-1-哌阱基)-4 -氧- 3-1¾啉羧酸1/2水 復 是合物之問題而進行研究之結果 發現1-琛丙基-6 -氟-1 ·£ ·4 -二氣-8 -甲氣基-7-(3 -甲基-1-呢阱基)-4 -氣-3 -技咐 g 羧酸3/2水合物為安定之化合物,製劑上也優。也即卜 ^;* ' ^ 環丙基-6-氣-1,4-二筐-8-甲《基- 7-(3-甲基- :[-哌阱基) ^ -4-氣-p-fff啉羧酸3/2水合物在廣泛菔度條件下安定, 且錠劑之崩散性及溶出性也佳。 又發現獲得1-環丙基- δ-氰-1,4-二氫-8-甲氣基-7-(3-甲基-1-哌阱基)-4-氧-3-吱啉羧酸3/2水合物之手段, 將1-環丙基-6-氣-1,4-二氳-8-甲氣基- 7-(3-甲基-1-哌 阱基卜4-氣-3-技啉羧酸之水懸浮液加热抿拌則高效率 地得目的物,终於完成本發明。 該水懸浮液乃指精裂階段酸齡再结晶畤中和後之懸浮 液,於單離之結晶加水之懸浮液等,水董為可以對結晶 之3〜20倍操作,但宜用3〜5倍可高産率得目的物。 溫度可在如50〜100*0 ,宜80〜90*C攛拌10〜30分。 水懸浮液之pH宜中性附近(6.0〜δ.0)。 加熱攢拌後,濾取目的物,將母液降至室溫邸可回收 二次結晶,故可提高産率》 -4 - 本紙張尺度速用中國國家揉率(CNS > A4*l格ί 210X297公釐) n^i I m ^ - --1 -----( (請先H讀背面之注意事項再填寫本頁)
,1T 經濟部中央標準局貝工消费合作社印袈 A7 _ B7 __ 五、發明説明(1 ) 技術領域 本發明為有關安定性優異之如下式U)卜琛丙基-6-氟 -1,4 -二氫-8-甲氣基- 7- (3 -甲基-1-哌阱基)-4 -氧-3-晻 啉羧酸3/2水合物及其製法。 技術背聚 授啉酮羧酸条抗菌劑近年急速發展,因具有從革蘭陽 性菌至陰性豳之廣泛抗菌譜及強力抗藥性,故尿路感染 症以外之外科感染症也被採用,備受有用性离之評價, 在瞳床上有莫大之貢獻。 尤其1-環丙基-6-氣-1,4-二氫-8 -甲氣基- 7-(3-甲基 -1-派阱基)-4-氣-3-»啉羧酸不但抗@力優,且對細菌 之選擇性高,選擇毒性也镊而顔受瞩目。 在特開昭62-25 27 72»掲示如下式(2)卜琛丙基-6-« -1,4-二氬-8-甲氣基-7-(3-甲基-1-瞅畊基>-4-氣-3-11 啉羧酸之1/2水合物。 (請先閲讀背面之注意事項再填窝本頁) .裝. 訂
線 經濟部中央橾準局員工消費合作杜印製 1-琢丙基-6-氣-1,4-二氫-8-甲氣基-7-(3-甲基-1-瞅 畊基卜4-氣-3-眭林羧酸因吸濕性強,故易形成水合物, 從含水有機溶剤再结晶,或將依酸-驗再結晶之中和晶 析法所得之結晶予以乾燦,則易成為1/2水合物。 但«知1-環丙基-6-氟-1,4 -二氳-8-甲氧基- 7- (3 -甲 一 3 - 本紙張尺度適用中因國家梯丰(CNS >今4规格(210X297公釐)
修 五、發明説明(2 ) 4 基-卜哌阱基)-4 -氣-3-丨f啉羧酸1/2水合物随濕度之上 | 昇而重量增加,若作成錠劑時有崩散性及溶出性不佳等 裂劑化上問題。 '心 發明之掲示 . 卜 . 本發明者們為解決上述1-瓌丙基-6-毎:-1,4-二氳-8- 甲氣基-7-(3 -甲基-1-哌阱基)-4 -氧- 3-1¾啉羧酸1/2水 復 是合物之問題而進行研究之結果 發現1-琛丙基-6 -氟-1 ·£ ·4 -二氣-8 -甲氣基-7-(3 -甲基-1-呢阱基)-4 -氣-3 -技咐 g 羧酸3/2水合物為安定之化合物,製劑上也優。也即卜 ^;* ' ^ 環丙基-6-氣-1,4-二筐-8-甲《基- 7-(3-甲基- :[-哌阱基) ^ -4-氣-p-fff啉羧酸3/2水合物在廣泛菔度條件下安定, 且錠劑之崩散性及溶出性也佳。 又發現獲得1-環丙基- δ-氰-1,4-二氫-8-甲氣基-7-(3-甲基-1-哌阱基)-4-氧-3-吱啉羧酸3/2水合物之手段, 將1-環丙基-6-氣-1,4-二氳-8-甲氣基- 7-(3-甲基-1-哌 阱基卜4-氣-3-技啉羧酸之水懸浮液加热抿拌則高效率 地得目的物,终於完成本發明。 該水懸浮液乃指精裂階段酸齡再结晶畤中和後之懸浮 液,於單離之結晶加水之懸浮液等,水董為可以對結晶 之3〜20倍操作,但宜用3〜5倍可高産率得目的物。 溫度可在如50〜100*0 ,宜80〜90*C攛拌10〜30分。 水懸浮液之pH宜中性附近(6.0〜δ.0)。 加熱攢拌後,濾取目的物,將母液降至室溫邸可回收 二次結晶,故可提高産率》 -4 - 本紙張尺度速用中國國家揉率(CNS > A4*l格ί 210X297公釐) n^i I m ^ - --1 -----( (請先H讀背面之注意事項再填寫本頁)
,1T 經濟部中央標準局貝工消费合作社印袈 A7 B7 3 五、發明説明( 圈面之簡單說明 第1圖為本發明品之熱分析結果,第2圖為比較品之 熱分析結果,第3圖為本發明品之IR,第4圄為比較品 之IR,第5圃為本發明品之X光撓射結果,第6團為比 較品之X光燒射結果,第7圖為本發明品之结晶構造之 説明圖。 實施本發明之最佳形態 下面舉實施例詳述本發明,但本發明不限於這些實施 例。 , 實施例1 將1-環丙基-6-氣-1,4-二氫-8-甲氣基-7-(3-甲基-1-哌阱基)-4-氣-3-K啉羧酸85克懸浮於水(425·1, 5倍 量),在内溫8 0〜8 5 Ό Κ拌1 0分後,在同溫乘熱過濾而 乾燥,得目的物84.43克,精製率92.7劣。 元素分析(%): CuHziFHii 〇4 ,3/2Η2 0 C Η Η 水分 6.26 10.44 6.7 6.15 10.44 7.3 經濟部中央標準局員工消費合作社印裝 計算值:56.71 實澜值·♦ 56.79 (1)使用機器 TG/ DTA IR分光光度計 X光燒射裝置 理學罨氣(TAS-200 ;控制部) TG8101D2 (測定裝置) 日立製作所270 -30形 理學霄氣2013型 單结晶X光繞射裝置:理學電氣AFC5R型 本紙張尺度逋用中國國家梂準< CNS ) A4规格(210X297公釐) 經濟部中央標準局員工消費合作社印裝 A7 _ ___B7_ 五、發明説明(4 ) 卡弗雪-水分計 :京都電子工業 HKA-3P型 1) 熱分析(TG/ DTA> 本發明品及未經熱水處理之比較品之試料各用約long ,以ct-氣化鋁為對照,從室溫以昇溫速度5Ό /分加熱 至240 ¾,此時之重量變化及熱受化分別測定,结果本 發明品如第1團,比較品如第2 Η。 2) IR 本發明品及未熱水處理之未處理品之各試料依KBr法 由透遇法澜定,结果本發明品如圈3,比較品如圏4。 ,3)粉末X光繞射 将本發明品及比較品之各試料粉碎,用玻璃試料板澜 定,結果本發明品如圔5,比較品如圈β。 4)單結晶X光繞射 X光縛射之結果,所得結晶構迪如圔7。 1-環丙基-6-氟-1,4-二氬-8-甲氣基-7-(3-甲基-1-哌 哄基)-4-氣-3-技啉羧酸3/2水合物在一般保穿择件下保 持一定之水分董而安定。 比較未處理品及本發明之熱水處理品之熱分析(TG/ DTA >,IR及粉末X光鐮射之拥定數據,則顯然樣式不同,熱 水處理品之结晶形明黷地與未處理品不同。 又從X光结晶繞射之結果,證明卜環丙基-6-氰-1,4-二氫-8-甲氧基-7-(3-甲基-1-哌畊基)-4-氧-3-ϋ啉羧 酸3/2水合物在單位晶格中含有1-璨丙基二 氬-8-甲氧基- 7-(3-甲基-1-哌阱基)-4-氣- 3_KW羧酸 -6 _ (請先聞讀背面之注意事項再填窝本頁) •裝· 訂 線 本紙張尺度通用中鬮國家梯準(CNS ) A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(5 ) 8分子及水12分子。 産業上之利用可能性 本發明之1-環丙基-6-氟-1,4-二氫-8-甲氣基-7-(3-甲基-1-哌阱基)-4-氣-3-睹W羧酸3/2水合物不但崩散 性及溶出性均優,且安定,故製劑上極為有用。 (請先閲讀背面之注意事項再填寫本頁) Γ 裝. 訂 Γ 線 本紙張尺度適用中國國家梂準(CNS ) A4規格(210X297公釐)
Claims (1)
- 申請專利範圍 A8 B8 C8 D8 η補充 年 (89年1月21日修正)COOH •3/2H20 第841 13 1 76號「安定性優異之8-烷氧基喹啉酮羧酸水合物及其製 法」專利案 公告衣: 六申請專利範圍: 1. 一種如下式1-環丙基-6-氟-1,4 -二氫-8-甲氧基-7 (3 -甲基-1-哌哄基)-4 -氧-3-喹啉羧酸3/2水合物, (1) 其特徵在於具有繞射角(2 Θ)爲 7.7。、9.1°、12.9。、 18.2° 、 19.9° ' 21.0° ' 25.30 、 27.8° ° 2. —種製造如申請專利範圍第1項之化合物之方法,其 特徵爲將液性在中性附近的1-環丙基-6-氟-1,4-二氫-8-甲氧基-7-(3-甲基-1-派哄基)-4-氧-3-睦琳竣酸之 3~20倍的水懸浮液加溫到50〜100°C,攪拌10至30 分鐘。 -Λ------訂----'--《I (請先閣讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 申請專利範圍 A8 B8 C8 D8 η補充 年 (89年1月21日修正)COOH •3/2H20 第841 13 1 76號「安定性優異之8-烷氧基喹啉酮羧酸水合物及其製 法」專利案 公告衣: 六申請專利範圍: 1. 一種如下式1-環丙基-6-氟-1,4 -二氫-8-甲氧基-7 (3 -甲基-1-哌哄基)-4 -氧-3-喹啉羧酸3/2水合物, (1) 其特徵在於具有繞射角(2 Θ)爲 7.7。、9.1°、12.9。、 18.2° 、 19.9° ' 21.0° ' 25.30 、 27.8° ° 2. —種製造如申請專利範圍第1項之化合物之方法,其 特徵爲將液性在中性附近的1-環丙基-6-氟-1,4-二氫-8-甲氧基-7-(3-甲基-1-派哄基)-4-氧-3-睦琳竣酸之 3~20倍的水懸浮液加溫到50〜100°C,攪拌10至30 分鐘。 -Λ------訂----'--《I (請先閣讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33556994A JP3449658B2 (ja) | 1994-12-21 | 1994-12-21 | 安定性に優れた8−アルコキシキノロンカルボン酸水和物並びにその製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW393479B true TW393479B (en) | 2000-06-11 |
Family
ID=18290056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW084113176A TW393479B (en) | 1994-12-21 | 1995-12-11 | Stable 8-alkoxy quinolone carboxylic acid hydrate and the preparation thereof |
Country Status (15)
Country | Link |
---|---|
US (1) | US5880283A (zh) |
EP (1) | EP0805156B1 (zh) |
JP (1) | JP3449658B2 (zh) |
KR (1) | KR100381644B1 (zh) |
CN (1) | CN1137890C (zh) |
AT (1) | ATE216381T1 (zh) |
AU (1) | AU694946B2 (zh) |
CA (1) | CA2208704C (zh) |
DE (1) | DE69526453T2 (zh) |
DK (1) | DK0805156T3 (zh) |
ES (1) | ES2173982T3 (zh) |
HU (1) | HU227795B1 (zh) |
PT (1) | PT805156E (zh) |
TW (1) | TW393479B (zh) |
WO (1) | WO1996019472A1 (zh) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9820405D0 (en) * | 1998-09-18 | 1998-11-11 | Smithkline Beecham Plc | Process |
GB9920919D0 (en) | 1999-09-03 | 1999-11-10 | Sb Pharmco Inc | Novel compound |
GB9920917D0 (en) | 1999-09-03 | 1999-11-10 | Sb Pharmco Inc | Novel process |
TWI287987B (en) * | 2000-08-14 | 2007-10-11 | Senju Pharma Co | Cytokine inhibitor |
US6413969B1 (en) * | 2000-09-13 | 2002-07-02 | Bristol-Myers Squibb Company | Gatifloxacin pentahydrate |
JP2002363172A (ja) * | 2001-06-05 | 2002-12-18 | Showa Denko Kk | 5−アルキルオキサゾリジン−2,4−ジオンの製造方法 |
US6589955B2 (en) | 2001-06-20 | 2003-07-08 | Bristol-Myers Squibb Company | Pediatric formulation of gatifloxacin |
KR100517638B1 (ko) | 2002-04-08 | 2005-09-28 | 주식회사 엘지생명과학 | 게미플록사신 산염의 새로운 제조방법 |
AU2003230831A1 (en) * | 2002-04-08 | 2003-10-27 | Dr. Reddy's Laboratories Limited | ANHYDROUS CRYSTALLINE FORMS I AND II OF 1-CYCLOPROPYL-6-FLUORO-8-METHOXY-7-(3-METHYL-1-PIPERAZINYL) 4-OXO-l, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID (GATIFLOXACIN) |
EP1503762A2 (en) * | 2002-05-10 | 2005-02-09 | Teva Pharmaceutical Industries Ltd. | Novel crystalline forms of gatifloxacin |
US7423153B2 (en) * | 2002-05-10 | 2008-09-09 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of gatifloxacin |
EP1645274A1 (en) * | 2002-05-10 | 2006-04-12 | Teva Pharmaceutical Industries Ltd. | Process for making gatifloxacin form omega |
CA2489377A1 (en) * | 2002-06-14 | 2003-12-24 | Valerie Niddam-Hildesheim | Novel crystalline forms of gatifloxacin |
CA2494518A1 (en) | 2002-08-06 | 2004-02-12 | Teva Pharmaceutical Industries Ltd. | Novel crystalline forms of gatifloxacin |
WO2004069825A1 (en) * | 2002-08-14 | 2004-08-19 | Teva Pharmaceutical Industries Ltd. | Synthesis of gatifloxacin |
WO2004054583A1 (en) * | 2002-12-12 | 2004-07-01 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of gatifloxacin and processes for preparation |
US20050085640A1 (en) * | 2003-04-02 | 2005-04-21 | Hetero Drugs Limited | Novel crystalline forms of gatifloxacin |
WO2004101547A1 (en) * | 2003-05-19 | 2004-11-25 | Hetero Drugs Limited | Purification methods of gatifloxacin and a novel form of gatifloxacin |
WO2005021000A1 (en) * | 2003-08-28 | 2005-03-10 | Ranbaxy Laboratories Limited | Solid oral dosage forms of gatifloxacin |
ES2232310B1 (es) * | 2003-11-13 | 2006-08-01 | Quimica Sintetica, S.A. | Formula cristalina no higroscopica de gatifloxacino. |
ES2232311B1 (es) * | 2003-11-13 | 2006-08-01 | Quimica Sintetica, S.A. | Forma cristalina de gatifloxacino. |
US7781585B2 (en) | 2004-06-04 | 2010-08-24 | Matrix Laboratories Ltd | Crystalline forms of Gatifloxacin |
US20090156577A1 (en) * | 2004-09-09 | 2009-06-18 | Benjamin Davis | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones |
US20060247255A1 (en) * | 2005-05-02 | 2006-11-02 | Patel Satishkumar A | Method for preparing a stable gatifloxacin composition |
US20080139574A1 (en) | 2006-11-30 | 2008-06-12 | Cadila Healthcare Limited | Novel quinoline derivatives |
CA2621616A1 (en) * | 2007-02-19 | 2008-08-19 | Alcon Research, Ltd. | Topical gatifloxacin formulations |
US7902227B2 (en) | 2007-07-27 | 2011-03-08 | Janssen Pharmaceutica Nv. | C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents |
US7884099B2 (en) * | 2007-11-16 | 2011-02-08 | Cumbre Ip Ventures, L.P. | Quinolone carboxylic acid-substituted rifamycin derivatives |
JP2013510097A (ja) * | 2009-11-03 | 2013-03-21 | リウ、リー | タンシノンiiaスルホン酸ナトリウム水和物、並びにその調製方法及び使用 |
CN102757419B (zh) * | 2012-08-08 | 2015-03-11 | 四川百利药业有限责任公司 | 一种加替沙星的纯化方法 |
MX2019001633A (es) | 2016-08-12 | 2019-09-18 | Silk Tech Ltd | Proteina derivada de la seda para el tratamiento de la inflamacion. |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3985747A (en) * | 1974-05-24 | 1976-10-12 | Bristol-Myers Company | Crystalline sesquihydrate of 7-[D-α-amino-α-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid |
JPS57134482A (en) * | 1981-02-13 | 1982-08-19 | Dainippon Pharmaceut Co Ltd | 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8- naphthyridine-3-carboxylic acid-3/2 hydrate and its preparation |
DE3248506A1 (de) * | 1982-12-29 | 1984-07-05 | Bayer Ag, 5090 Leverkusen | 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7(alkyl-1-piperazinyl)-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel |
JPH089597B2 (ja) * | 1986-01-21 | 1996-01-31 | 杏林製薬株式会社 | 選択毒性に優れた8‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法 |
JPS62205060A (ja) * | 1986-03-04 | 1987-09-09 | Kyorin Pharmaceut Co Ltd | 8位置換キノロンカルボン酸誘導体 |
CN1019114B (zh) * | 1986-03-31 | 1992-11-18 | 三共株式会社 | 喹啉-3-羟酸衍生物的制备方法 |
JPS63198664A (ja) * | 1986-03-31 | 1988-08-17 | Sankyo Co Ltd | キノロンカルボン酸誘導体 |
CA2128601C (en) * | 1992-01-31 | 2003-07-15 | Hiroyuki Nagano | Quinolone carboxylic acid derivatives in crystalline hydrate form |
-
1994
- 1994-12-21 JP JP33556994A patent/JP3449658B2/ja not_active Expired - Lifetime
-
1995
- 1995-12-05 US US08/860,325 patent/US5880283A/en not_active Expired - Lifetime
- 1995-12-05 DE DE69526453T patent/DE69526453T2/de not_active Expired - Lifetime
- 1995-12-05 KR KR1019970704228A patent/KR100381644B1/ko not_active IP Right Cessation
- 1995-12-05 AT AT95938644T patent/ATE216381T1/de active
- 1995-12-05 AU AU39946/95A patent/AU694946B2/en not_active Expired
- 1995-12-05 HU HU9800908A patent/HU227795B1/hu unknown
- 1995-12-05 DK DK95938644T patent/DK0805156T3/da active
- 1995-12-05 WO PCT/JP1995/002477 patent/WO1996019472A1/ja active IP Right Grant
- 1995-12-05 CN CNB951969838A patent/CN1137890C/zh not_active Expired - Lifetime
- 1995-12-05 EP EP95938644A patent/EP0805156B1/en not_active Expired - Lifetime
- 1995-12-05 CA CA002208704A patent/CA2208704C/en not_active Expired - Lifetime
- 1995-12-05 PT PT95938644T patent/PT805156E/pt unknown
- 1995-12-05 ES ES95938644T patent/ES2173982T3/es not_active Expired - Lifetime
- 1995-12-11 TW TW084113176A patent/TW393479B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HU227795B1 (en) | 2012-03-28 |
CA2208704A1 (en) | 1996-06-27 |
JPH08176143A (ja) | 1996-07-09 |
CN1171108A (zh) | 1998-01-21 |
US5880283A (en) | 1999-03-09 |
AU694946B2 (en) | 1998-08-06 |
ATE216381T1 (de) | 2002-05-15 |
DE69526453T2 (de) | 2002-12-12 |
DE69526453D1 (de) | 2002-05-23 |
KR100381644B1 (ko) | 2003-08-30 |
CN1137890C (zh) | 2004-02-11 |
AU3994695A (en) | 1996-07-10 |
EP0805156A4 (en) | 1998-04-15 |
EP0805156A1 (en) | 1997-11-05 |
EP0805156B1 (en) | 2002-04-17 |
DK0805156T3 (da) | 2002-05-06 |
ES2173982T3 (es) | 2002-11-01 |
PT805156E (pt) | 2002-09-30 |
JP3449658B2 (ja) | 2003-09-22 |
HUT77945A (hu) | 1998-12-28 |
CA2208704C (en) | 2005-05-03 |
WO1996019472A1 (fr) | 1996-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW393479B (en) | Stable 8-alkoxy quinolone carboxylic acid hydrate and the preparation thereof | |
TWI322805B (zh) | ||
CN87103693A (zh) | 喹啉-3-羟酸衍生物和其制备及应用 | |
JP2017137330A (ja) | 4−tert−ブチル−N−[4−クロロ−2−(1−オキシ−ピリジン−4−カルボニル)−フェニル]−ベンゼンスルホンアミドのナトリウム塩の多形 | |
CN109678715A (zh) | 2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途 | |
US11414388B2 (en) | Crystal form of 3-(4-methyl-1h-imidazol-1-yl)-5-trifluoromethylaniline monohydrochloride and use thereof | |
JPS61197577A (ja) | 1−置換−6−フルオロ−7−(ピロ−ル−1−イル)−1,4−ジヒドロ−4−オキソキノリン−3−カルボン酸誘導体およびその製造法 | |
RU2248355C2 (ru) | 8-циан-1-циклопропил-7-(1s,6s-2,8-диазабицикло[4,3,0]нонан-8-ил)-6- фтор-1, 4-дигидро-4-оксо-3-хинолинкарбоновая кислота кристаллической модификации в и лекарственное средство на ее основе, обладающее действием против патогенных бактерий | |
Jacobs et al. | CHEMOTHERAPY OF TRYPANOSOME AND SPIROCHETE INFECTIONS: CHEMICAL SERIES. I. N-PHENYLGLYCINEAMIDE-p-ARSONIC ACID. | |
JP5628816B2 (ja) | リコフェロンのコリンおよびトロメタミン塩 | |
TW576835B (en) | Crystal modification A of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo(4.3.0)nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | |
JPH01242582A (ja) | キノロンカルボン酸化合物i型結晶の製造法 | |
US10717729B2 (en) | Thiamine-organic acid salt | |
TW393478B (en) | Novel crystal forms of 1-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-pyridinyl] piperazine | |
US2009086A (en) | Devitalization of bacteria | |
WO2018076117A1 (en) | Novel salts of nilotinib and crystalline forms thereof | |
EP0189679B1 (en) | Novel crystalline form of 1-benzhydryl-4-allylpiperazine dihydrochloride and method for the production thereof | |
Whitmore et al. | PARA-CHLOROMERCURI-BENZOIC ACID AND RELATED COMPOUNDS1: Preliminary Paper | |
Morgan et al. | 219. Arsonic acids of the fluorenone series. Derivatives of aminofluorenone-2-arsonic acid | |
Smith | 57. Alkaline halogenation. Part I. The chlorination of sodium benzoate | |
Town | The separation of amino-acids by means of their copper salts: The hydrolysis of gliadin. An investigation of the dicarboxylate fraction, including the isolation of r-glutamic acid as an hydrolysis product | |
AT401648B (de) | Verfahren zur herstellung von 1-subst.-6-fluor- | |
Mane | SYNTHESIS, CHARACTERISATION AND ANTIMICROBIAL EVALUATION OF SOME NEW PYRROLE-2-CARBOXAMIDE DERIVATIVES | |
Kitasato et al. | 102. Preliminary synthetic experiments in the morphine group. Part III. Some derivatives of papaveroline and laudanosoline | |
JPH0331288A (ja) | 特定な結晶形態にある9,1―エポキシメタノ―7―フルオロ―8―(4―メチル―1―ピペラジニル)―5―オキソ―5H―チアゾロ[3,2―a]キノリン―4―カルボン酸・塩酸塩の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MK4A | Expiration of patent term of an invention patent |